Premium
Oral ivermectin for a scabies outbreak in a long‐term care facility: potential value in preventing COVID‐19 and associated mortality
Author(s) -
Bernigaud C.,
Guillemot D.,
AhmedBelkacem A.,
GrimaldiBensouda L.,
Lespine A.,
Berry F.,
Softic L.,
Chenost C.,
DoPham G.,
Giraudeau B.,
Fourati S.,
Chosidow O.
Publication year - 2021
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.19821
Subject(s) - ivermectin , moxidectin , outbreak , case fatality rate , antiparasitic agent , medicine , population , scabies , pandemic , covid-19 , long term care , intensive care medicine , environmental health , disease , veterinary medicine , virology , dermatology , infectious disease (medical specialty) , nursing
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom